Becton, Dickinson And Company

Becton, Dickinson And Company's Infectious Disease Systems (IDS) division manufactures and supplies diagnostic laboratory equipment, blood culture analyzers, microbiology testing systems, and related reagents and consumables to federal healthcare agencies as a large prime contractor competing on a full-and-open, non-set-aside basis. The IDS division is a subsidiary of parent Becton, Dickinson And Co, headquartered in Franklin Lakes, New Jersey, a for-profit corporation with no SBA certifications.

BD's federal contracting footprint spans 2,862 awards—nearly all prime (100%)—with 2.8 billion dollars in combined potential value across 76 customer agencies. The company's award trajectory has accelerated sharply: 47 awards in 2024 to 129 in 2025, with 85 awards year-to-date in 2026. Activity concentrates in laboratory diagnostic equipment and in vitro diagnostic substances, with top NAICS codes including Analytical Laboratory Instrument Manufacturing (701 awards), In-Vitro Diagnostic Substance Manufacturing (271 awards), and Medical Equipment and Supplies Merchant Wholesaling (245 awards). Top PSC categories are Laboratory Equipment and Supplies (904 awards) and Medical and Surgical Instruments and Equipment (646 awards).

Customer concentration aligns to federal healthcare demand. The Defense Logistics Agency Troop Support Medical leads by both award count (254 awards, $237 million combined potential value) and dollars—32% of the portfolio's combined value flows to DLA. The Defense Health Agency (49 awards, $32.1 million), the Department of the Army Medical Command (65 awards, $21 million), and Veterans Integrated Service Network 4 (91 awards, $16 million) anchor the next tier. The Veterans Health Administration represents the single largest customer ecosystem, with 30+ VISN-specific delivery orders and BPAs spanning blood culture systems, BACTEC analyzers, MGIT mycobacterial detection platforms, and cost-per-test diagnostic services across regional VA medical facilities.

BD holds position on multiple parent vehicles. The GSA Schedule for Critical Analyzers, Laboratory (FSS-66-III) is by far the largest—406 task orders worth $54.1 million—reflecting BD's dominance in federal blood culture and microbiology analyzer procurement. A $49 million single-award indefinite delivery contract with DLA (awarded June 2026, extending through June 2031) covers laboratory equipment and supplies to Department of Defense and other federal laboratories worldwide. Single-award BPAs with the Defense Health Agency ($7 million, through April 2030) and Veterans Integrated Service Network 2 ($678,674, through October 2030) provide streamlined procurement frameworks for diagnostic testing equipment and blood culture supplies. Named IDIQs include a $1.3 million Veterans Integrated Service Network 17 contract for BD MAX reagents and diagnostic services (awarded August 2026, through August 2029) and a $1.5 million NIH Clinical Center contract for flow cytometry instrument rental and reagents (through December 2026).

Recent representative work spans BD's diagnostic portfolio: a $1,948,685 Defense Health Agency delivery order for microbiology analyzer services supporting Naval Hospital Jacksonville, Florida, through March 2031; a $1,275,000 Veterans Integrated Service Network 17 purchase order for a CTX microbiology automation system with dual workstations (August 2026); a $711,285 Veterans Integrated Service Network 17 contract for BD Synapsys service support and software subscription (December 2025); and a $247,841 Defense Health Agency BPA call for testing kits and microbiology supplies to Walter Reed. Smaller-dollar delivery orders—typically $1,000 to $50,000—flow continuously through the Medical Supply Chain for blood culture bottles, BACTEC reagents, AFFIRM diagnostic kits, and Phoenix calibrators. The company also supplies flow cytometry instruments (BD FACsLyric platform) and associated reagents to the NIH Clinical Center and provides maintenance and computer services for laboratory equipment at Indian Health Service facilities.

A recompete cliff of $40.5 million in combined potential value faces completion over the next twenty-four months—42 awards with ultimate completion dates between October 2026 and October 2027, representing significant recompete exposure and opportunity for incumbents and competitors.

SCI-reported service contract activity is minimal, reflecting BD's business model as a goods and equipment supplier rather than labor-intensive service provider. SCI records total $263 thousand invoiced across FY2023–FY2025, with 0.1 FTEs reported in FY2023; this subset excludes the vast majority of BD's federal revenue, which flows through product sales, equipment leases, and cost-per-test diagnostic services.

BD subcontracts to Cardinal Health 200, LLC on medical and surgical supply orders (whole blood collection kits, sensors, gloves, and regional distribution), but the sub-award footprint represents 0.5% of total awards—the company operates predominantly as a prime. The IDS division's federal strategy leverages its position as the original equipment manufacturer for BACTEC, MGIT, BD MAX, and AFFIRM platform systems, enabling sole-source maintenance and reagent procurement justifications under FAR 6.302-1 across military, VA, and civilian healthcare agencies.